Vadim Yu Bogachev

Prof. Dr. Vadim Yu Bogachev

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in International Angiology
Verified
Journal Article
Closed access
VBVadim Yu Bogachev
Vadim Yu Bogachev
BBBoris V. Boldin
Boris V. Boldin
VLVictor N. Lobanov
Victor N. Lobanov
Article: Benefits of micronized purified flavonoid fraction as adjuvant therapy on inflammatory response after sclerotherapy - International Angiology 2018 February;37(1):71-8 - Minerva Medica - Journals

15 June 2018 in Advances in Therapy
Verified
Journal Article
Open access
PDF file
VBVadim Yu Bogachev
Vadim Yu Bogachev
BBBoris V. Boldin
Boris V. Boldin
PTPavel Y. Turkin
Pavel Y. Turkin
Introduction Sclerotherapy is a common technique for the removal of intradermal veins. This study examined the rationale for prescribing micronized purified flavonoid fraction (MPFF) in clinical, etiological, anatomic, pathophysiologic (CEAP) class C1 patients with dilated intradermal veins scheduled for sclerotherapy. Methods In a national, multicenter, observational program, physicians recruited CEAP C1s patients scheduled for sclerotherapy. The decision to prescribe adjuvant MPFF (1000 mg/day for 6 weeks beginning 2 weeks before sclerotherapy) was made according to usual practice. Disease severity and treatment outcomes were assessed at baseline and 4 weeks post-sclerotherapy using a visual analog scale (VAS) as well as quality-of-life (CIVIQ-14) and patient satisfaction (Darvall) questionnaires. Results A total of 70 physicians recruited 1150 patients: 1071 (93%) women, 79 (7%) men. Mean age (± SD) was 40.7 ± 10.7 years (range 18–74) and mean body mass index was 23.6 ± 3.3 kg/m2. Reticular veins were observed in 42.1% of patients and 57.9% had telangiectasias. MPPF was prescribed to 905 patients (79%). Sclerotherapy was associated with statistically significant decreases in mean VAS scores for leg heaviness, pain, sensation of swelling, night cramps, and itching. For each symptom, MPFF-treated patients showed a more pronounced improvement than those undergoing sclerotherapy alone: mean VAS pain score with MPFF decreased from 1.90 ± 2.30 to 0.30 ± 0.62 versus 1.72 ± 1.93 to 0.52 ± 0.99 with sclerotherapy alone; mean VAS leg heaviness score with MPFF decreased from 2.80 ± 2.43 to 0.47 ± 1.07 versus 2.38 ± 2.23 to 0.76 ± 0.85 with sclerotherapy alone. Patient quality-of-life indicators improved with symptom resolution, particularly pain, and for each indicator the observed improvement was greater with MPFF. The outcomes of treatment exceeded patient expectations. Fewer patients experienced sclerotherapy-induced hyperpigmentation with adjunctive MPFF versus sclerotherapy alone (33.9% versus 41.2%, respectively, P = 0.034). No adverse events related to MPFF were observed. Conclusion Resolution of venous symptoms post-sclerotherapy was greater in patients treated with MPFF compared with those undergoing sclerotherapy alone, supporting the rationale for use of MPFF in patients undergoing sclerotherapy. Funding Servier.

27 May 2019 in Drugs & Therapy Perspectives
Verified
Journal Article
Open access
PDF file
VBVadim Yu Bogachev
Vadim Yu Bogachev
JAJosé Manuel Jiménez Arribas
José Manuel Jiménez Arribas
SBSorin Baila
Sorin Baila
JDJorge Ulloa Dominguez
Jorge Ulloa Dominguez
JWJohannes Walter
Johannes Walter
AMAndres Marin
Andres Marin
The aim of this study was to examine worldwide chronic venous disease (CVD) burden and evaluate effectiveness, adherence and satisfaction with conservative treatment.

7 November 2020 in Lasers in Medical Science
Verified
Journal Article
Closed access
PDF file
VMVladimir P. Minaev
Vladimir P. Minaev
NMNikita Minaev
Nikita Minaev
VBVadim Yu Bogachev
Vadim Yu Bogachev
KKKonstantin A. Kaperiz
Konstantin A. Kaperiz
Vladimir YusupovVladimir Yusupov
Vladimir Yusupov

1 January 2019 in Angiology and vascular surgery
Verified
Journal Article
Closed access
VBVadim Yu Bogachev
Vadim Yu Bogachev
BBB. V. Boldin
B. V. Boldin
PTP. Iu. Turkin
P. Iu. Turkin
The study was aimed at assessing efficacy and safety of using a micronized purified flavonoid fraction in the perioperative period in patients scheduled for endovascular surgical intervention for CEAP clinical class C2 lower limb varicose veins. This study enrolled a total of 1519 patients with CEAP C2a,sEpAs (primary varicose vein with valvular incompetence of the great and/or small saphenous vein) who were subdivided into two groups. Group One included 1039 patients who in the perioperative period were prescribed a micronized purified flavonoid fraction at a daily dose of 1000 mg and who continued therapy, including visit 4. Group Two was composed of 480 patients taking no venoactive agents. The main criterion for assessing efficacy of the micronized purified flavonoid fraction was the incidence rate of typical adverse events in the compared groups of patients after surgical intervention. The patients receiving the micronized purified flavonoid fraction were found to have adverse events significantly less often as compared with those in the control group: ecchymosis 7.1 versus 11.0% (p=0.01), haematoma 0.5 vs 1.3% (p=0.1), paresthesia 0.5 vs 1.7% (p=0.02), thrombophlebitis 0.2 vs 0.6% (p=0.2), pigmentation 0.6 vs 3.3% (p=0.001), heat-induced thrombosis 0.3 vs 1.3% (p=0.02). The total incidence rate of adverse events in patients receiving and those not receiving the micronized purified flavonoid fraction amounted to 7.6 vs 15.0%, respectively (<0.001). The micronized purified flavonoid fraction prescribed in the perioperative period, owing to a pluripotent mechanism, adapts the venous system and microcirculatory bed of the lower extremities to operative stress, decreasing the anti-inflammatory response to endovascular intervention, lowering thereby the incidence of undesirable events. Prescription of the micronized purified flavonoid fraction in the perioperative period ensures a significant decrease in the incidence of typical adverse events developing after endovascular surgical treatment for CEAP clinical class C2 varicose veins and may be recommended for real clinical practice.

25 August 2022 in Future Cardiology
Verified
Journal Article
Open access
VBVadim Yu Bogachev
Vadim Yu Bogachev
BBBoris Boldin
Boris Boldin
PTPavel Turkin
Pavel Turkin
ASAlexander Samenkov
Alexander Samenkov
ODOlga Dzhenina
Olga Dzhenina
Aims: To investigate the effectiveness and tolerability of adjunctive micronized purified flavonoid fraction (MPFF) in patients with chronic venous disease (CVD). Patients & methods: This observati... Plain language summary Chronic venous disease (CVD) can cause a range of signs and symptoms that reduce patient quality of life. Micronized purified flavonoid fraction (MPFF) is a type of venoactiv... Tweetable abstract Micronized-purified-flavonoid-fraction-based conservative treatment reduced chronic venous disease symptoms and improved quality of life in patients with advanced-stage chronic v...